leisure time -WSS

leisure time

author：focus 2025-09-03 14:37:50 - browse：21

Editor’s note: A recording of the event is embedded below.

Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for?

Let’s dive in and discuss what to watch in the months ahead.

Speakers:

Alex Brill, CEO, Matrix Global Advisors
Chris Brown, managing partner and co-founder, Integrity Rx Partners
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)
Thomas Newcomer, head of U.S. market access, Samsung Bioepis (sponsor speaker)

Previous article： Drug repurposing or repositioning? The language matters
Next article： BioAge raises $170M for combination therapy with Zepbound

leisure time

WSS

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

NIH chief: government has fallen behind pharma on clinical trials

Vaccine advisory panel ACIP left half staffed by HHS

Publishing genetic code of viruses could cause disaster

Today's health inequities arise from racist U.S. history, say experts

FDA reorg will put new emphasis on investigations, sources say

hotspot

leisure time

focus

Walensky prepares to leave CDC — and Congress — behind

Why did Pfizer dish out millions for a Super Bowl ad?

Hollywood unions extend contract negotiations for actors

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Continuity nursing helped my family in our darkest PICU moments

The Readout: Gilead, Bernie Sanders, and other pharma news

Novavax promises a turnaround & Lilly roils the obesity market

After decades in use, heart stents finally beat placebo

Medical leaders decry Supreme Court decision on affirmative action

Biden report: The neurospychology of memory and aging

explore

First transplant of an entire human eye performed

NIH chief: government has fallen behind pharma on clinical trials

Gilead might be held responsible for not developing a drug

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

A letter from the executive editor: STAT UnitedHealth investigation

'Revelatory' study finds a smoking impact that remains after quitting

focus

hotspot

leisure time

knowledge